Statistics

Total Visits

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r54

Select a period of time:

Number of views in the range

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r35

Views

Views
March 202516
April 20252
May 20251
June 20250
July 202514
August 20252
September 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
Brazil8
United States7
Spain1
United Kingdom1
Trinidad and Tobago1
South Africa1
 

Top cities views

Views
Ashburn2
Bedford1
Belford Roxo1
Caratinga1
Centurion1
Chaguanas1
Council Bluffs1
Itajubá1
Manchester1
New York1